Mbiomics Raises €30M Series A To Advance Microbiome Therapeutics

The round includes existing investors like MIG Fonds and Bayern Kapital. The funding will help the company move from building its platform to running clinical studies and scaling manufacturing.

mbiomics, founded in 2020 by Johannes Wöhrstein, Markus Rinecker, and Laura Figulla, aims to unlock the gut microbiome’s full immunological and metabolic potential to treat disease.

The company develops complex microbiome-based therapeutics using proprietary analytics and patient insights to create targeted microbial communities tailored to specific conditions and patient needs.

Read Also - German Biotech Startup Primogene Raises €4.1M Seed Funding

Its core products are Live Biotherapeutic Products (LBPs) oral treatments composed of live bacterial strains designed to restore the gut microbiome’s functional balance in a scalable, pharmaceutical-grade format.

mbiomics highlights that while faecal microbiota transplants (FMTs) have shown clinical success, they remain variable and difficult to scale positioning its approach as a more consistent and industrially viable alternative.

mbiomics highlights growing clinical evidence showing that modulating the gut microbiome can improve responses to immune checkpoint inhibitors in oncology.

Building on this, the company is initially targeting second-line melanoma with its lead candidate MBX-116 as a co-therapy, aiming to enhance treatment outcomes. A Phase 1B clinical study is planned for 2027.

The new funding will support strengthening IND-enabling pharmacological data, as well as accelerating GMP development and manufacturing in preparation for clinical evaluation.

Beyond oncology, mbiomics is advancing a broader pipeline of microbiome-based therapeutics, with potential applications in autoimmune and neurodegenerative diseases where the gut microbiome plays a key role.

“While the clinical potential of the gut microbiome is well understood, transforming microbiome-based therapeutics into a scalable product has remained a significant engineering challenge. At mbiomics, we are solving this challenge by building the full technology stack for the design, analysis, screening, and manufacturing of complex microbial consortia. We are now focused on advancing our lead candidate, MBX-116, towards clinical evaluation,” said Dr Johannes B. Woehrstein, CEO and co-founder of mbiomics.

About Mbiomics

mbiomics is a biotech company working to use the human microbiome to improve health. It develops tools and targeted treatments to better understand microbes helping create more precise therapies and support healthier lives.